FORESEE Data at SNO 2024

Plus Therapeutics to Present Positive FORESEE Clinical Trial Data at SNO Annual Meeting in Houston

Plus Therapeutics is thrilled to present groundbreaking results from the FORESEE Clinical Trial at the Society for Neuro-Oncology (SNO) Annual Meeting in Houston. The study demonstrated the significant utility of the CNSide™ Cerebrospinal Fluid (CSF) Assay in diagnosing and managing leptomeningeal metastases (LM), a critical complication in patients with metastatic cancer.

Key Findings from the FORESEE Trial:

• Successful Trial Endpoints: The FORESEE trial successfully met its primary and secondary endpoints, confirming the effectiveness of the CNSide CSF Assay in detecting leptomeningeal metastasis (LM).
• Influence on Clinical Management: The assay influenced clinical management decisions in over 90% of LM cases, showcasing its potential to enhance decision-making and treatment strategies.
• Improved Diagnostic Sensitivity: The CNSide CSF Assay demonstrated 2.8 times the diagnostic sensitivity compared to standard cytology, offering a more accurate and reliable method for diagnosing LM in patients.

Why This Data Matters for Leptomeningeal Metastasis and Cancer Care

Leptomeningeal metastasis is a devastating complication that occurs when cancer spreads to the membranes surrounding the brain and spinal cord. Early and accurate diagnosis is critical for improving patient outcomes. The CNSide CSF Assay offers a promising new diagnostic tool that could significantly impact the management of brain cancer, lung cancer, breast cancer, and other forms of metastatic cancer that lead to LM.

Learn More About the FORESEE Trial and CNSide CSF Assay Results:

For a detailed summary of the clinical trial and the findings presented at SNO, visit the full press release: Plus Therapeutics Press Release

#LeptomeningealMetastasis #CNSideAssay #CerebrospinalFluid #BrainCancer #LungCancer #BreastCancer #MetastaticCancer #SNO2024 #CancerDiagnostics #CNSCancer #ClinicalTrials #CancerTherapeutics #OncologyResearch #RadiationTherapy #BrainMetastasis #DiagnosticSensitivity #CancerCare #PSTV